Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, P.O. Box 80205, Jeddah, 21589, Saudi Arabia,
Eur J Clin Pharmacol. 2013 Dec;69(12):1985-96. doi: 10.1007/s00228-013-1563-z. Epub 2013 Aug 17.
To study and analyze the comparative impact of hospital-acquired adverse drug reactions (ADRs) in adult and pediatric patients in terms of the economic implications, (length of) hospital stay, and salient features in relation to the incidence rate, severity, morbidity, mortality, and preventability of the ADRs.
A systematic search to identify and retrieve relevant articles/studies in the PubMed, Medline, Scopus, MEDPAR, and Cochrane databases and by the Google search engine was performed for the study period 2000 to April 2013. In total, 51 studies were identified on patients hospitalized for ADRs, and these were included in the study. The incidence rate of ADRs, their severity, mortality, morbidity, preventability, cost, and association with extended hospital stay due to ADRs were extracted and scrutinized.
Hospital-acquired ADRs are more widely studied in adults than in children, and the incidence rate is higher in the former. However, a wide variation in the incidence rate worldwide is observed in both groups. Irrespective of the ages of patients, ADRs are among the most frequent causes of morbidity and mortality. Interestingly, preventable ADRs are more frequently observed in patients at the younger and older ends of the age spectrum. Hospital-acquired ADRs place an immense economic burden on healthcare systems, with the overall cost for a hospitalized patient with an ADR reported to be $2,401 per patient, which is equivalent to a 19.86 % additional increase in the total cost of care and an increase in average length of hospital stay of 8.25 %.
Based on the findings of this review, we suggest that excellent assertive measures of pharmacovigilance with the aim to diminish the incidence rate of hospital-acquired ADRs and support the development of interventions are needed to promote vital facets of drug safety with an overall objective to avert potential ADRs.
研究和分析成人和儿科患者医院获得性药物不良反应(ADR)在经济影响、(住院)时间长短以及与 ADR 发生率、严重程度、发病率、死亡率和可预防性关系方面的相对影响。
对 2000 年至 2013 年 4 月期间在 PubMed、Medline、Scopus、MEDPAR 和 Cochrane 数据库以及谷歌搜索引擎中进行了系统搜索,以识别和检索相关文章/研究。共确定了 51 项关于因 ADR 住院患者的研究,并将这些研究纳入研究。提取并审查了 ADR 的发生率、严重程度、死亡率、发病率、可预防性、成本以及与 ADR 导致的住院时间延长的关系。
与儿童相比,医院获得性 ADR 在成人中得到了更广泛的研究,并且前者的发生率更高。然而,在这两个群体中,全球范围内的发生率差异很大。无论患者年龄大小,ADR 都是发病率和死亡率的最常见原因之一。有趣的是,在年龄较小和较大的患者中,更常观察到可预防的 ADR。医院获得性 ADR 给医疗保健系统带来了巨大的经济负担,据报道,每位因 ADR 住院的患者的总费用为 2401 美元,这相当于护理总成本增加了 19.86%,平均住院时间延长了 8.25%。
根据本综述的结果,我们建议需要采取出色的药物警戒措施,以降低医院获得性 ADR 的发生率,并支持干预措施的制定,以促进药物安全的重要方面,总体目标是避免潜在的 ADR。